Almirall’s 2025 Results February 23, 2026 Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory. This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM). The continued strong performance of the biologics portfolio is the backbone of Almirall’s growth, with Ilumetri® net sales increasing 12.3% YoY (total of €234.4 MM), and Ebglyss® net sales increasing more than 3x YoY to a total of €110.8 MM – reflecting its strong position and growth trajectory across Europe in the second year after launch. Continued solid performance of the broad dermatology product portfolio with Wynzora® growing 30.5% YoY to a total of €33.8 MM, and Klisyri® growing 33.9% YoY to a total of €32.8 MM, further enhances Almirall’s position as trusted partner for patients and dermatologists. Almirall’s business performance fuels the advancement of a diversified and innovative R&D pipeline addressing skin diseases with high unmet need. Pipeline progress in 2025 included the start of the phase II study of the anti-IL-1RAP mAb in Hidradenitis suppurativa, the start of the phase II study of the IL-2muFc in Alopecia areata, and the approval of Jublia® in Germany and Seysara® in China. Guidance for 2026: net sales growth of 9%-12% and total EBITDA between €270 MM and €290 MM.
AHS Tower Fully Sold During Development, Generating More Than USD 700 Million February 23, 2026 A new commercial landmark on Sheikh Zayed Road underscores market momentum for next-generation workspaces in Dubai.
INCERGO S.A. Announces Share Capital Increase and Strategic Shareholding with Visual Semiconductor February 23, 2026 INCERGO S.A. (Symbol: ICG) announces that, effective February 19, 2026, its issued share capital has increased from 5,060,000 to 151,283,387 registered ordinary shares. The issuance of 146,223,387 new shares has been duly registered and is effective on the Vienna Stock Exchange as of today. The company announced further progress in its merger with Visual Semiconductor [...]
Capitolis to Acquire 20 Gates Management’s U.S. Secured Financing Platform to Expand its Capital Marketplace February 20, 2026 Strategic acquisition enables Capitolis to deliver U.S. secured financing through its Capital Marketplace, broadens client base, and adds veteran industry talent
Telekom Srbija Group Announces Platinum Sponsorship of EXPO 2027 Belgrade February 20, 2026 Telekom Srbija to power EXPO 2027 and unveil dedicated pavilion showcasing its technology ecosystem
Cloudflare and Mastercard Partner to Extend Comprehensive Cyber Defense Across Critical Infrastructure and Small Businesses February 17, 2026 Combined security offerings will uncover hidden risks, assess security posture, and automate defenses for all web-facing assets
North Highland Welcomes Nyla Beth Gawel as Senior Managing Director February 17, 2026 Gawel's appointment strengthens the firm's workforce strategy expertise
Corpay Cross-Border Named the Official Commercial FX Partner of Prima Pramac Racing February 17, 2026 Providing access to currency risk management and cross-border payments solutions
Allegion (NYSE: ALLE) Reports Q4, Full-Year 2025 Financial Results, Introduces 2026 Outlook February 17, 2026 High-Single Digit Revenue Growth for the Enterprise and Continued Strength in Americas Non-Residential Quarterly Financial Highlights (All comparisons are year-over-year, unless otherwise noted) Net earnings per share (EPS) of $1.70, up 3.0% compared with $1.65; Adjusted EPS of $1.94, up 4.3% compared with $1.86 Revenues of $1,033.2 million, up 9.3% on a reported basis and up 3.3% on an organic basis Operating margin of 20.3%, compared with 19.5%; Adjusted operating margin of 22.4%, compared with 22.1% Full-Year Financial Highlights (All comparisons are year-over-year, unless otherwise noted) EPS of $7.44, up 9.1% compared with $6.82; Adjusted EPS of $8.14, up 8.1% compared with $7.53 Revenues of $4,067.3 million, up 7.8% on a reported basis and up 4.1% on an organic basis Operating margin of 21.1%, compared with 20.7%; Adjusted operating margin of 23.2%, up 40 basis points compared with 22.8% Available cash flow, which is defined as net cash from operating activities minus capital expenditures, was $685.7 million for 2025, an increase of 17.6% 2026 Full-Year Outlook Highlights Full-year reported revenue growth is estimated to be 5% to 7%, with organic revenue growth estimated to be 2% to 4% Full-year adjusted EPS is estimated to be $8.70 to $8.90 Available cash flow is estimated to be 85% to 95% of adjusted net income
Endava Partners with Miro to Drive Innovative New Model for AI Transformation February 17, 2026 Strategic partnership embeds Miro AI platform across Endava's global offering to strengthen its AI-native delivery model
